ATE486286T1 - Prognoseverfahren für kongestives herzversagen - Google Patents
Prognoseverfahren für kongestives herzversagenInfo
- Publication number
- ATE486286T1 ATE486286T1 AT05757019T AT05757019T ATE486286T1 AT E486286 T1 ATE486286 T1 AT E486286T1 AT 05757019 T AT05757019 T AT 05757019T AT 05757019 T AT05757019 T AT 05757019T AT E486286 T1 ATE486286 T1 AT E486286T1
- Authority
- AT
- Austria
- Prior art keywords
- heart failure
- congestive heart
- methods
- natriurctic
- combination
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 206010007559 Cardiac failure congestive Diseases 0.000 title abstract 3
- 206010019280 Heart failures Diseases 0.000 title abstract 3
- 238000004393 prognosis Methods 0.000 title 1
- 230000004083 survival effect Effects 0.000 abstract 3
- 108050009340 Endothelin Proteins 0.000 abstract 1
- 102000002045 Endothelin Human genes 0.000 abstract 1
- 238000011366 aggressive therapy Methods 0.000 abstract 1
- 230000001746 atrial effect Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5754—Endothelin, vasoactive intestinal contractor [VIC]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55485904P | 2004-03-19 | 2004-03-19 | |
| PCT/IB2005/002063 WO2005089045A2 (en) | 2004-03-19 | 2005-03-18 | Prognostic methods for congestive heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE486286T1 true ATE486286T1 (de) | 2010-11-15 |
Family
ID=34994109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05757019T ATE486286T1 (de) | 2004-03-19 | 2005-03-18 | Prognoseverfahren für kongestives herzversagen |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070212729A1 (de) |
| EP (4) | EP2264463A3 (de) |
| AT (1) | ATE486286T1 (de) |
| DE (1) | DE602005024389D1 (de) |
| DK (1) | DK1756583T3 (de) |
| ES (1) | ES2352845T3 (de) |
| WO (1) | WO2005089045A2 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
| AU2007233320B2 (en) | 2006-04-04 | 2013-12-12 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
| WO2010144358A1 (en) | 2009-06-08 | 2010-12-16 | Singulex, Inc. | Highly sensitive biomarker panels |
| JP7270912B2 (ja) * | 2017-05-22 | 2023-05-11 | 東ソー株式会社 | アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU731858B2 (en) * | 1997-09-11 | 2001-04-05 | Shionogi & Co., Ltd. | Immunoassay for BNP |
| AUPQ048799A0 (en) * | 1999-05-20 | 1999-06-10 | Monash University | Diagnosis of cardiovascular disease |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
-
2005
- 2005-03-18 DE DE602005024389T patent/DE602005024389D1/de not_active Expired - Lifetime
- 2005-03-18 US US10/593,372 patent/US20070212729A1/en not_active Abandoned
- 2005-03-18 EP EP10183974A patent/EP2264463A3/de not_active Withdrawn
- 2005-03-18 WO PCT/IB2005/002063 patent/WO2005089045A2/en not_active Ceased
- 2005-03-18 DK DK05757019.4T patent/DK1756583T3/da active
- 2005-03-18 AT AT05757019T patent/ATE486286T1/de active
- 2005-03-18 ES ES05757019T patent/ES2352845T3/es not_active Expired - Lifetime
- 2005-03-18 EP EP05757019A patent/EP1756583B1/de not_active Expired - Lifetime
- 2005-03-18 EP EP10184000A patent/EP2267456A3/de not_active Withdrawn
- 2005-03-18 EP EP10183988A patent/EP2267455A3/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20070212729A1 (en) | 2007-09-13 |
| EP1756583A2 (de) | 2007-02-28 |
| EP2267456A3 (de) | 2011-08-17 |
| ES2352845T3 (es) | 2011-02-23 |
| EP2267455A2 (de) | 2010-12-29 |
| DE602005024389D1 (de) | 2010-12-09 |
| EP2264463A3 (de) | 2011-08-10 |
| EP1756583B1 (de) | 2010-10-27 |
| DK1756583T3 (da) | 2011-02-14 |
| WO2005089045A2 (en) | 2005-09-29 |
| WO2005089045A3 (en) | 2006-07-20 |
| EP2264463A2 (de) | 2010-12-22 |
| EP2267455A3 (de) | 2012-01-04 |
| EP2267456A2 (de) | 2010-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3059322T3 (da) | Genekspressionsmarkører for brystcancerprognose | |
| WO2008146309A3 (en) | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
| WO2010056351A3 (en) | Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and out come prediction in pedeatric b-precursor acute lymphoblastic leukemia | |
| MX2020010815A (es) | Biomarcadores para enfermedad de injerto contra hospedero. | |
| MX2009000385A (es) | Acil-anilidas sustituidas y metodos de uso de las mismas. | |
| GEP20166454B (en) | Sclerostin binding agents | |
| UA86582C2 (ru) | Способ лечения хореи гентингтона ейкозапентеновой кислотой | |
| CR10022A (es) | Agentes que se enlazan con un objetivo en el tejido pulmonar para el tratamiento de enfermedades respiratorias | |
| WO2004071572A3 (en) | Gene expression markers for response to egfr inhibitor drugs | |
| WO2004111273A3 (en) | Gene expression markers for response to egfr inhibitor drugs | |
| IL183284A0 (en) | Methods and compositions for treating ocular disorders | |
| WO2008030273A3 (en) | Compositions and methods for diagnosis and treatment of type 2 diabetes | |
| WO2005039382A3 (en) | Prediction of likelihood of cancer recurrence | |
| WO2007041245A3 (en) | Biomarkers for multiple sclerosis and methods of use thereof | |
| NZ574046A (en) | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration | |
| SG156625A1 (en) | Method for measuring resistance or sensitivity to docetaxel | |
| ATE520032T1 (de) | Differentielle cytokinexpression bei einer menschlichen krebserkrankung | |
| WO2007067476A3 (en) | Methods for predicting treatment response based on the expression profiles of protein and transcription biomakers | |
| EP1987165A4 (de) | Gene mit einfluss auf die menschliche gedächtnisleistung | |
| DE602005024389D1 (de) | Prognoseverfahren für kongestives herzversagen | |
| NO20054913L (no) | Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser | |
| WO2005110479A3 (en) | Treatments for pancreatic cancer | |
| WO2015121737A3 (en) | Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure | |
| ATE416756T1 (de) | Methoden zur verwendung von lamellaren körpern für therapeutische zwecke | |
| WO2010102160A3 (en) | Diagnostic method using palb2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1756583 Country of ref document: EP |